Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences, in collaboration with Arcus Biosciences, recently completed a clinical study titled ‘A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.’ The study aimed to assess the antitumor activity and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer, a significant area of unmet medical need.
The study tested several interventions, including the experimental drug etrumadenant, a dual adenosine receptor antagonist, in combination with other drugs such as zimberelimab, a monoclonal antibody, and standard chemotherapy regimens like mFOLFOX-6. The goal was to enhance treatment efficacy against metastatic colorectal cancer.
This interventional study was randomized with a parallel assignment model, focusing on treatment as its primary purpose. It employed single masking, where the outcomes assessor was blinded to the treatment assignments, ensuring unbiased results.
The study began on December 3, 2020, with its primary completion and estimated completion dates not specified. The last update was submitted on October 17, 2025, indicating the study’s completion and the availability of updated information.
The completion of this study could influence Gilead Sciences’ stock performance positively, as successful results may enhance investor confidence and market position in oncology. Competitors in the metastatic colorectal cancer treatment space may need to adjust strategies in response to these findings.
The study has been completed, and further details are available on the ClinicalTrials portal.